Deprescribing consistently reduces medication burden without increasing adverse outcomes, and pharmacists are the best-positioned profession to lead these efforts across PPIs, benzodiazepines, opioids, anticholinergics, and overaggressive antihyperglycemics in elderly patients.
Key Results
Polypharmacy affects approximately 40% of adults aged 65 and older. Up to 70% of PPI prescriptions lack a documented indication. Kua et al. (2019) meta-analysis: pharmacist-led deprescribing reduced mortality (OR 0.90, 95% CI 0.82-0.99). AHRQ Making Healthcare Safer IV (2024, PMID 38349984) identifies deprescribing as a key patient safety intervention.
Clinical Interpretation
The evidence supports deprescribing as safe and effective for reducing medication burden. While clear mortality and hospitalization benefits are inconsistent (likely reflecting underpowered studies), the consistent finding is that removing unnecessary medications does not cause harm, and reduces polypharmacy-related adverse effects including falls, cognitive decline, and drug interactions.
Pharmacist Action Items
Integrate deprescribing into every comprehensive medication review: screen against Beers Criteria, STOPP/START v3, and anticholinergic burden calculators.
Prioritize high-yield targets: PPIs without ongoing indication, benzodiazepines in elderly (Beers: avoid regardless of indication), chronic opioids without functional improvement, and anticholinergic stacking.
For PPI deprescribing: step down (BID to daily), then taper (50% reduction every 1-2 weeks), then switch to H2RA or as-needed. Educate on rebound acid hypersecretion (resolves in 2-4 weeks).
For benzodiazepine deprescribing: reduce by 10-25% every 1-2 weeks (slower than expected). Consider converting short-acting to long-acting for smoother taper. Offer CBT-I for insomnia.
Track and document deprescribing outcomes: PIMs reduced, total medications decreased, patient-reported outcomes, falls, and cost savings. Build the business case using MTM CPT codes.
Address the overtreatment of diabetes in elderly: A1c targets should be relaxed (avoid <7% in patients with limited life expectancy, dementia, or functional impairment) per ADA 2026 deintensification framework.
Deprescribing Targets
Class
Problem
Approach
Caution
PPIs
Up to 70% without documented indication
Step down, taper, switch to H2RA/PRN
Rebound acid hypersecretion (2-4 weeks)
Benzodiazepines/Z-drugs
Falls, cognitive impairment, paradoxical agitation in elderly
10-25% reduction every 1-2 weeks, consider CBT-I
Slower taper than expected; never abrupt discontinuation
Chronic opioids
No functional improvement, adverse effects
5-10% reduction every 2-4 weeks, multimodal pain management
Never abrupt discontinuation
Anticholinergics
Cumulative burden increases dementia, falls, delirium
Identify stacking with ACB Scale, substitute alternatives
Overtreatment causes hypoglycemia, falls, CV events
Relax A1c targets, reduce sulfonylureas/insulin
ADA 2026 deintensification framework
Evidence-Based Frameworks & Tools
Deprescribing.org algorithms.
Beers Criteria 2023.
STOPP/START v3 2023.
MedStopper.
STOPPFall.
ACB Scale.
Key Reference
TitleAHRQ Making Healthcare Safer IV
Pmid38349984
Year2024
Guideline Context
Beers Criteria 2023 (AGS), STOPP/START v3 (2023), deprescribing.org evidence-based algorithms, ADA 2026 deintensification framework, AHRQ Making Healthcare Safer IV (2024). STOPPFall tool specifically targets fall-risk medications.
Editor's Note
AHRQ report verified: PMID 38349984. Deprescribing.org algorithms are the most widely validated tools. Key gap: most deprescribing RCTs are underpowered for hard outcomes.